Article
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Nature communications - 5 Feb 2021
Bakouny Ziad, Braun David A, Shukla Sachet A, Pan Wenting, Gao Xin, Hou Yue, Flaifel Abdallah, Tang Stephen, Bosma-Moody Alice, He Meng Xiao, Vokes Natalie, Nyman Jackson, Xie Wanling, Nassar Amin H, Abou Alaiwi Sarah, Flippot Ronan, Bouchard Gabrielle, Steinharter John A, Nuzzo Pier Vitale, Ficial Miriam, Sant'Angelo Miriam, Forman Juliet, Berchuck Jacob E, Dudani Shaan, Bi Kevin, Park Jihye, Camp Sabrina, Sticco-Ivins Maura, Hirsch Laure, Baca Sylvan C, Wind-Rotolo Megan, Ross-Macdonald Petra, Sun Maxine, Lee Gwo-Shu Mary, Chang Steven L, Wei Xiao X, McGregor Bradley A, Harshman Lauren C, Genovese Giannicola, Ellis Leigh, Pomerantz Mark, Hirsch Michelle S, Freedman Matthew L, Atkins Michael B, Wu Catherine J, Ho Thai H, Linehan W Marston, McDermott David F, Heng Daniel Y C, Viswanathan Srinivas R, Signoretti Sabina, Van Allen Eliezer M, Choueiri Toni K
Abstract excerpt
Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly aggressive tumors with limited molecular and clinical characterization. Emerging evidence suggests immune checkpoint inhibitors (ICI) are particularly effective for these tumors, although the biological basis for this property is largely unknown. Here, we evaluate multiple clinical trial and real-world cohorts of S/R RCC to characterize their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.